Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A future for neonatal alpha1-antitrypsin screening?

T Sveger1, T Thelin

  • 1Department of Paediatrics, University of Lund, University Hospital, Malmö, Sweden.

Acta Paediatrica (Oslo, Norway : 1992)
|April 20, 2000
PubMed
Summary

Neonatal screening for alpha1-antitrypsin deficiency (alpha1ATD) is recommended by WHO experts. Early detection aids in managing liver disease and preventing emphysema, with screening timing debated due to smoking risks and psychosocial factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age of SERPINA1 gene PI Z mutation: Swedish and Latvian population analysis.

Annals of human genetics·2008
Same author

Plasma neutrophil lipocalin, elastase-alpha1-antitrypsin complex and neutrophil protease 4 in preterm infants with respiratory distress syndrome.

Scandinavian journal of clinical and laboratory investigation·2003
Same author

Tracheobronchial aspirate fluid neutrophil lipocalin, elastase- and neutrophil protease-4-alpha1-antitrypsin complexes, protease inhibitors and free proteolytic activity in respiratory distress syndrome.

Acta paediatrica (Oslo, Norway : 1992)·2002
Same author

A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies in Swedish children and adolescents.

Acta paediatrica (Oslo, Norway : 1992)·2002
Same author

Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).

Thorax·2002
Same author

A future for neonatal alpha1-antitrypsin screening?

Acta paediatrica (Oslo, Norway : 1992)·2000

Area of Science:

  • Medical Genetics
  • Public Health
  • Pediatrics

Background:

  • Alpha1-antitrypsin deficiency (alpha1ATD) affects 1 in 5000 in the US and up to 1 in 500 in Europe.
  • alpha1ATD is a significant risk factor for neonatal liver disease and adult-onset emphysema.
  • Smoking drastically reduces life expectancy and the asymptomatic period for individuals with alpha1ATD.

Purpose of the Study:

  • To evaluate the benefits and drawbacks of neonatal screening for alpha1-antitrypsin deficiency (alpha1ATD).
  • To discuss the optimal timing for alpha1ATD screening, considering early intervention versus the age of smoking initiation.
  • To address the psychosocial implications and potential discrimination associated with alpha1ATD screening.

Main Methods:

  • Review of WHO expert recommendations on alpha1ATD screening.

Related Experiment Videos

  • Analysis of data from the Swedish alpha1AT screening program.
  • Discussion of potential advantages and disadvantages of neonatal versus school-age screening.

    • Main Results:

    • Neonatal screening enables early diagnosis and treatment of liver disease in infants with alpha1ATD.
    • Information and advice provided during screening can deter adolescents from smoking, as seen in the Swedish program.
    • Debate continues regarding the optimal screening age due to psychosocial concerns and the effectiveness of anti-smoking advice.

    Conclusions:

    • Neonatal screening for alpha1ATD offers benefits for early disease management and smoking prevention.
    • The timing of screening remains a critical consideration, balancing early intervention with potential psychosocial impacts and child participation.
    • Further research is needed to address uncertainties regarding screening participation, psychosocial reactions, and the efficacy of anti-smoking interventions.